Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus HYDROCHLOROTHIAZIDE IRBESARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus HYDROCHLOROTHIAZIDE IRBESARTAN.
BENICAR HCT vs HYDROCHLOROTHIAZIDE; IRBESARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Irbesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the AT1 receptor, blocking vasoconstriction and aldosterone secretion.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Hydrochlorothiazide 12.5-25 mg and irbesartan 150-300 mg orally once daily. Maximum dose: hydrochlorothiazide 25 mg/day; irbesartan 300 mg/day.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment); Irbesartan: 11-15 hours (supports once-daily dosing).
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Renal: 70% (irbesartan, unchanged and metabolites); 95% (hydrochlorothiazide, unchanged). Fecal: 30% (irbesartan).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB